Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today provided clinical updates and reported financial results for the second quarter ended June 30, 2013.
Clinical Updates
Our lead clinical candidate is ganetespib, a selective inhibitor of the Hsp90 chaperone protein, which is being evaluated in over 25 clinical trials that have enrolled over a thousand patients to date, including our GALAXY program in lung cancer and our ENCHANT program in breast cancer.
Help employers find you! Check out all the jobs and post your resume.
